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Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs 
worldwide. More NSAIDs were being produced and manufactured everyday. It was an 
overwhelming view that the thought of all NSAIDs were important due to their 
therapeutic actions by inhibiting the production of prostaglandin was challenged by the 
discovery that they affect a wide variety of cellular processes along the way. The 
NSAIDs piroxicam and mefenamic acid have dissimilar chemical structures, enolic 
and carboxylic acid respectively, but with the same mode of action for therapeutic uses. 
They both inhibit prostaglandin synthesis by inhibiting the cyc100xygenase (COX) 
pathway as of other conventional NSAIDs. However in some cases, they did differ 
with each other depending on the gravity of their effects on certain aspects. 
Although the toxicity of piroxicam was well known and documented, mefenamic acid 
is still not the safest drugs of all. Histologically, mefenamic acid showed a marked 
toxicity to the liver and kidney of rats compared to piroxicam. Morphological changes 
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such as inflammation and fibrosis of liver were frequently observed in repeated doses 
of mefenamic acid with elevation of protein plasma alkaline phosphatase (ALP) and 
alanine transferase (AL T), higher than piroxicam. Piroxicam on the other hand, did 
cause higher toxicity in the gastrointestinal tract but not significant to mefenamic acid. 
Nevertheless, both drug showed a significant different (p<0.05) when compared to 
control in post-treated plasma levels and also the mean lesion scores of samples treated 
with repeated doses of NSAIDs. 
Using liver perfusion technique, freshly isolated rat hepatocytes were obtained for the 
in vitro treatment of NSAIDs. The cell viability test was done by trypan blue exclusion. 
As a result both piroxicam and mefenamic acid caused reduction in cell viability of 
hepatocytes up to 50% of cell death at highest concentration. However, mefenamic 
acid exerted its cytotoxicity even more so than piroxicam in both time- and dose­
dependent manner. Meanwhile, the effects of piroxicam and mefenamic acid on 
Phenobarbital-induced rat hepatocytes were not pronouncedly shown. It was 
concluded that Phenobarbital-induced rat hepatocytes did not alter the cytotoxicity of 
both drugs in both time- and dose- dependent fashion. 
Both piroxicam and mefenamic acid did significantly reduce the cell viability of cancer 
cells especially the colon cancer cells. MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide) assay was done to determine the cell viability of the 
cancer cells. Both colon cancer cells used (HCT 1 16 and Caco 2) showed a significant 
reduction in cell viability after being treated with both piroxicam and mefenamic acid. 
It was postulated that this event occurred due to their ability to inhibit the 
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prostaglandin synthesis which were upregulated in colon adenocarcinomas. That might 
be the possible reason behind the reduction of colon cancer cells' viability treated with 
NSAIDs. 
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Dadah anti-keradangan bukan steroid (NSAIDs) adalah kumpulan dadah yang paling 
meluas penggunaanya serata dunia. Lebih banyak NSAIDs telah dihasilkan dan 
dikeluarkan setiap hari. Ia adalah satu pandangan yang membingungkan tentang 
anggapan bahawa semua NSAIDs adalah sangat penting disebabkan oleh tindakan 
terapeutik mereka iaitu menyekat penghasilan prostaglandin, dicabar oleh penemuan 
yang mereka juga memberi pelbagai kesan yang meluas terhadap proses-proses sel 
sepanjang aktiviti itu. NSAIDs piroxicam dan asid mefenamik mempunyai struktur 
kimia yang berbeza, masing-masing asid enolik dan karboksilik, tetapi dengan gaya 
tindakan yang sama untuk kegunaan terapeutik. Kedua-duanya menyekat sintesis 
prostaglandin dengan menghalang laluan siklooksigenes (COX) sepertimana NSAIDs 
yang lain. Bagaimanapun, mereka memang berbeza di antara satu sama lain 
bergantung kepada tahap kesan masing-masing dalam sesetengah aspek. 
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Walaupun ketoksikan plroxlcam telah diketahui dan didokumentasikan, asid 
mefenamik masih juga bukan dadah yang paling selamat. Secara histologinya, asid 
mefenamik menunjukkan kesan ketoksikan yang ketara terhadap hati dan buah 
pinggang tikus-tikus berbanding piroxicam. Perubahan morfologi seperti keradangan 
dan fibrosis pada hati telah dilihat dengan kerap dalam suntikan asid mefenamik 
secara berulang-kali dengan peningkatan terhadap plasma protein alkalin fosfatase 
(ALP) dan alanin trasferase (ALT) yang lebih tinggi berbanding piroxicam. Piroxicam 
pula memberi kesan ketoksikan yang lebih tinggi pada saluran pencemaan tetapi ia 
tidak signifikan berbanding asid mefenamik. Namun demikian, kedua-duanya 
menunjukkan perbezaan yang signifikan (p<0.05) apabila dibandingkan dengan 
kawalan pada tahap plasma selepas rawatan dan juga min skor lesi bagi sampel yang 
dirawat oleh NSAIDs secara berulang-kali. 
Dengan menggunakan teknik perfusi hati, pengasingan sel hepatosit tikus segar dapat 
dibuat untuk digunakan dalam rawatan in vitro oleh NSAIDs. Ujian untuk menguji 
sel-sel hidup dibuat menggunakan trip an biru. Piroxicam dan asid mefenamik 
menyebabkan penurunan kepada bilangan sel hepatosit yang hidup sebanyak 50% 
kematian sel pada kepekatan yang tertinggi. Bagaimanapun, asid mefenamik 
menunjukkan kesan kesitotoksikan yang lebih tinggi berbanding piroxicam dalam 
keadaan berkadar langsung dengan masa dan dos. Sementara itu, kesan piroxicam dan 
asid mefenamik terhadap sel-sel hepatosit yang telah dirawat terlebih dahulu dengan 
Phenobarbital tidak ditunjukkan dengan ketara. Sebagai konklusi" sel-sel hepatosit 
yang telah dirawat dengan Phenobarbital tidak mengubah kesitotoksikan kedua-dua 
dadah dalam keadaan yang berkadar langsung dengan masa dan dos. 
VII 
Kedua-dua piroxicam dan asid mefenamik secara signifikan telah menurunkan 
bilangan sel-sel kanser yang hidup terutama sel-sel kanser bagi kolon. Esei MTT (3-
[4, 5-dimetilthiazol-2-yl]-2, 5-difeniltetrazolium bromid) telah dibuat untuk 
menentukan sel-sel kanser yang hidup. Kedua-dua sel kolon yang digunakan (HCT 
1 16 dan Caco 2) menunjukkan penurunan sel-sel hidup yang signifikan selepas 
dirawat oleh piroxicam dan asid mefenamik. Ia telah didakwa bahawa kejadian ini 
berlaku disebabkan oleh kemampuan mereka menyekat sintesis prostaglandin yang 
terdapat dengan banyaknya dalam adenokarsinoma. Mungkin itu adalah salah satu 
sebab kepada penurunan bilangan sel-sel kanser yang hidup selepas dirawat oleh 
NSAIDs. 
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4.5 Time-dependent cytotoxicity of piroxicam and mefenamic acid on rat 1 16 
hepatocytes at 1 .0 mM 
4.6 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 1 1 7 
hepatocytes at 0 .25 hr 
4.7 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 1 1 7 
hepatocytes at 0.5 hr 
4.8 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 1 18 
hepatocytes at 0.75 hr 
4.9 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 1 18 
hepatocytes at 1 hr 
4. 10 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 1 19 
hepatocytes at 2 hrs 
4. 1 1  Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 1 1 9 
hepatocytes at 3 hrs 
4. 12 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 120 
hepatocytes at 4 hrs 
4. 13 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 120 
hepatocytes at 5 hrs 
4. 14 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 121  
hepatocytes at  6 hrs 
5 . 1  Time-dependent cytotoxicity of piroxicam and mefenamic acid on rat 137 
hepatocytes at 0 .000 1 mM 
5 .2 Time-dependent cytotoxicity of piroxicam and mefenamic acid on rat 137 
hepatocytes at 0 .00 1 mM 
5 .3 Time-dependent cytotoxicity of piroxicam and mefenamic acid on rat 138 
hepatocytes at 0.0 1 mM 
XXlll 
5 .4 Time-dependent cytotoxicity of piroxicam and mefenamic acid on rat 138 
hepatocytes at 0. 1 mM 
5 .5 Time-dependent cytotoxicity of piroxicam and mefenamic acid on rat 139 
hepatocytes at 1 .0 mM 
5.6 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 1 40 
hepatocytes at 0 .25 hr 
5 .7 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 140 
hepatocytes at 0.5 hr 
5 .8 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 1 4 1  
hepatocytes at 0 .75 hr 
5 .9 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 14 1  
hepatocytes a t  1 hr 
5 . 10 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 142 
hepatocytes at 2 hrs 
5. 1 1  Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 142 
hepatocytes at 3 hrs 
5 . 12 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 143 
hepatocytes at 4 hrs 
5 . 13 Dose-dependent cytotoxicity of piroxicam and mefenamic acid on rat 143 
hepatocytes at 5 hrs 
5 . 14  Dose-dependent cytotoxicity of  piroxicam and mefenamic acid on rat 144 
hepatocytes at 6 hrs 
5 . 1 5  Comparison between control of Phenobarbital-induced and normal rat 149 
hepatocytes suspension after treatment with piroxicam and mefenamic 
acid 
5 . 16 Time-dependent cytotoxicity of piroxicam on Phenobarbital-induced 1 5 1  
and normal rat hepatocytes at 0.000 1 mM 
5 . 1 7  Time-dependent cytotoxicity of piroxicam on Phenobarbital-induced 1 52 
and normal rat hepatocytes at 0.00 1 mM 
5 . 18 Time-dependent cytotoxicity of piroxicam on Phenobarbital-induced 1 52 
and normal rat hepatocytes at 0.0 1 mM 
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